Cargando…
Combating poor-quality anti-malarial medicines: a call to action
The circulation of poor-quality medicines continues to undermine the fight against many life-threatening diseases. Anti-malarial medicines appear to have been particularly compromised and present a major public health threat in malaria-endemic countries, negatively affecting individuals and their co...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888506/ https://www.ncbi.nlm.nih.gov/pubmed/27251199 http://dx.doi.org/10.1186/s12936-016-1357-8 |
_version_ | 1782434863089975296 |
---|---|
author | Bassat, Quique Tanner, Marcel Guerin, Philippe J. Stricker, Kirstin Hamed, Kamal |
author_facet | Bassat, Quique Tanner, Marcel Guerin, Philippe J. Stricker, Kirstin Hamed, Kamal |
author_sort | Bassat, Quique |
collection | PubMed |
description | The circulation of poor-quality medicines continues to undermine the fight against many life-threatening diseases. Anti-malarial medicines appear to have been particularly compromised and present a major public health threat in malaria-endemic countries, negatively affecting individuals and their communities. Concerted collaborative efforts are required from global, regional and national organizations, involving the public and private sectors, to address the problem. While many initiatives are underway, a number of unmet needs deserve urgent and increased multisector attention. At the global level, there is a need for an international public health legal framework or treaty on poor-quality medicines, with statutes suitable for integration into national laws. In addition, increased international efforts are required to strengthen the governance of global supply chains and enhance cooperation between national medicine regulation authorities and law enforcement bodies. Increased investment is needed in innovative technologies that will enable healthcare teams to detect poor-quality medicines at all levels of the supply chain. At the regional level, a number of initiatives would be beneficial—key areas are standardization, simplification, and reciprocal recognition of registration processes and development of quality control capacity in regional centres of excellence that are better aligned with public health needs; improved surveillance methods and creation of a framework for compulsory and transparent reporting of poor-quality medicines; additional support for national medicine regulation authorities and other national partner authorities; and an increase in support for regional laboratories to boost their capabilities in detecting poor-quality medicines. It is vital that all stakeholders involved in efforts against poor-quality anti-malarial medicines extend and strengthen their actions in these critical areas and thus effectively support global health development and malaria elimination programmes. |
format | Online Article Text |
id | pubmed-4888506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48885062016-06-02 Combating poor-quality anti-malarial medicines: a call to action Bassat, Quique Tanner, Marcel Guerin, Philippe J. Stricker, Kirstin Hamed, Kamal Malar J Review The circulation of poor-quality medicines continues to undermine the fight against many life-threatening diseases. Anti-malarial medicines appear to have been particularly compromised and present a major public health threat in malaria-endemic countries, negatively affecting individuals and their communities. Concerted collaborative efforts are required from global, regional and national organizations, involving the public and private sectors, to address the problem. While many initiatives are underway, a number of unmet needs deserve urgent and increased multisector attention. At the global level, there is a need for an international public health legal framework or treaty on poor-quality medicines, with statutes suitable for integration into national laws. In addition, increased international efforts are required to strengthen the governance of global supply chains and enhance cooperation between national medicine regulation authorities and law enforcement bodies. Increased investment is needed in innovative technologies that will enable healthcare teams to detect poor-quality medicines at all levels of the supply chain. At the regional level, a number of initiatives would be beneficial—key areas are standardization, simplification, and reciprocal recognition of registration processes and development of quality control capacity in regional centres of excellence that are better aligned with public health needs; improved surveillance methods and creation of a framework for compulsory and transparent reporting of poor-quality medicines; additional support for national medicine regulation authorities and other national partner authorities; and an increase in support for regional laboratories to boost their capabilities in detecting poor-quality medicines. It is vital that all stakeholders involved in efforts against poor-quality anti-malarial medicines extend and strengthen their actions in these critical areas and thus effectively support global health development and malaria elimination programmes. BioMed Central 2016-06-01 /pmc/articles/PMC4888506/ /pubmed/27251199 http://dx.doi.org/10.1186/s12936-016-1357-8 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Bassat, Quique Tanner, Marcel Guerin, Philippe J. Stricker, Kirstin Hamed, Kamal Combating poor-quality anti-malarial medicines: a call to action |
title | Combating poor-quality anti-malarial medicines: a call to action |
title_full | Combating poor-quality anti-malarial medicines: a call to action |
title_fullStr | Combating poor-quality anti-malarial medicines: a call to action |
title_full_unstemmed | Combating poor-quality anti-malarial medicines: a call to action |
title_short | Combating poor-quality anti-malarial medicines: a call to action |
title_sort | combating poor-quality anti-malarial medicines: a call to action |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888506/ https://www.ncbi.nlm.nih.gov/pubmed/27251199 http://dx.doi.org/10.1186/s12936-016-1357-8 |
work_keys_str_mv | AT bassatquique combatingpoorqualityantimalarialmedicinesacalltoaction AT tannermarcel combatingpoorqualityantimalarialmedicinesacalltoaction AT guerinphilippej combatingpoorqualityantimalarialmedicinesacalltoaction AT strickerkirstin combatingpoorqualityantimalarialmedicinesacalltoaction AT hamedkamal combatingpoorqualityantimalarialmedicinesacalltoaction |